Tyrosine kinase inhibitorFDA-approvedFirst-line
BRAF/MEK Inhibitor Combination (Encorafenib + Binimetinib)
Generic name: encorafenib, binimetinib
How it works
Blocks the BRAF V600E mutation and the MEK protein, which are involved in the signaling pathway that drives cancer cell growth.
Cancer types
Melanoma— BRAF V600E-positive
Efficacy
Studies show that around 50% of patients achieved an objective response, with a median progression-free survival of approximately 14.9 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.